In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Haemonetics Corp’s stock clocked out at $73.77, up 1.68% from its previous closing price of $72.55. In other words, the price has increased by $1.68 from its previous closing price. On the day, 0.63 million shares were traded. HAE stock price reached its highest trading level at $74.34 during the session, while it also had its lowest trading level at $72.76.
Ratios:
To gain a deeper understanding of HAE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.88. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 1.56 whereas as Long-Term Debt/Eq ratio is at 1.18.
On June 26, 2025, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $87.
BofA Securities Downgraded its Neutral to Underperform on February 07, 2025, whereas the target price for the stock was revised from $95 to $68.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 26 ’25 when Llorens Josep bought 18,630 shares for $74.94 per share.
Strong Stewart W bought 708 shares of HAE for $50,593 on Jun 12 ’25. On Jun 04 ’25, another insider, Strong Stewart W, who serves as the Officer of the company, bought 7,705 shares for $69.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3543999232 and an Enterprise Value of 4559321088. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.24, and their Forward P/E ratio for the next fiscal year is 13.12. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.60 while its Price-to-Book (P/B) ratio in mrq is 4.33. Its current Enterprise Value per Revenue stands at 3.35 whereas that against EBITDA is 12.808.
Stock Price History:
The Beta on a monthly basis for HAE is 0.40, which has changed by -0.19612187 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $94.99, while it has fallen to a 52-week low of $55.30. The 50-Day Moving Average of the stock is 3.11%, while the 200-Day Moving Average is calculated to be 2.58%.
Shares Statistics:
It appears that HAE traded 559.17K shares on average per day over the past three months and 631820 shares per day over the past ten days. A total of 48.22M shares are outstanding, with a floating share count of 47.37M. Insiders hold about 1.38% of the company’s shares, while institutions hold 114.46% stake in the company. Shares short for HAE as of 1749772800 were 4059388 with a Short Ratio of 6.55, compared to 1747267200 on 4075152. Therefore, it implies a Short% of Shares Outstanding of 4059388 and a Short% of Float of 11.2399995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 11.0 analysts analyze and rate the current performance of Haemonetics Corp (HAE) in the stock market.The consensus estimate for the next quarter is $1.17, with high estimates of $1.24 and low estimates of $1.09.
Analysts are recommending an EPS of between $5.06 and $4.81 for the fiscal current year, implying an average EPS of $4.87. EPS for the following year is $5.62, with 9.0 analysts recommending between $5.85 and $5.4.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $305.12M. It ranges from a high estimate of $330.81M to a low estimate of $295.82M. As of the current estimate, Haemonetics Corp’s year-ago sales were $336.17MFor the next quarter, 11 analysts are estimating revenue of $321.48M. There is a high estimate of $345.47M for the next quarter, whereas the lowest estimate is $313.1M.
A total of 11 analysts have provided revenue estimates for HAE’s current fiscal year. The highest revenue estimate was $1.39B, while the lowest revenue estimate was $1.29B, resulting in an average revenue estimate of $1.31B. In the same quarter a year ago, actual revenue was $1.36BBased on 9 analysts’ estimates, the company’s revenue will be $1.41B in the next fiscal year. The high estimate is $1.45B and the low estimate is $1.38B.
